Pharmacovigilance Case Management Software: Why Adverse Event Intake, Coding and E2B Submission Break Under Volume

Why safety case processing collapses at exactly the wrong moment

A serious unexpected adverse reaction has a 15 calendar day expedited reporting clock in both the United States and the European Union. That clock starts at first receipt by anyone in your organisation, which includes a sales representative who was told something in a clinic corridor and mentioned it in an email three days later. The clock does not care that your triage queue is backed up, that the reporter is unreachable for follow up, or that your literature vendor delivered a batch late.

The volume shape is what breaks teams. Case load is not steady. A product launch, a media story, a patient support programme going live, or a partner sending a quarterly batch under a safety data exchange agreement can double intake in a week. A team sized for the average is underwater on the peak, and the failure is invisible until an inspection asks for on time submission rates by month and the number for March is not the number in the quarterly report.

The second structural problem is that a safety case is not a form. It is a versioned narrative with a seriousness assessment, an expectedness assessment against a specific reference safety information document version, a causality assessment, coded terms, and a submission history to multiple authorities each with their own version of the case. Follow up information arrives and the whole thing amends, which restarts obligations. Systems that model a case as a record rather than as a versioned object with a submission ledger produce reconciliation nightmares.

What Argus, ArisGlobal, Veeva and Ennov actually leave to you

Oracle Argus Safety is the incumbent that most large organisations run, and it is genuinely comprehensive. ArisGlobal LifeSphere Safety has invested heavily in automation. Veeva Vault Safety brings the advantages of a single platform for companies already deep in Vault. Ennov Safety is a credible option at a friendlier price point. None of these is a weak product and none of them fails at the core case processing job.

Where they cost organisations disproportionately is at the edges. Intake is the first. Adverse events arrive by email, from a call centre, from a partner in E2B files with their own quirks, from literature abstracts, from patient support programme vendors, from social media monitoring and from your own clinical systems. Every one of those is an intake channel that has to be triaged, deduplicated against existing cases and initiated inside the clock. Packaged systems handle structured E2B intake well and everything else through an inbox that a human works through.

The second is configuration turnaround. Adding a product, updating reference safety information, changing an expectedness rule or onboarding a new partner is a configuration task that in most organisations sits behind a validation cycle and a vendor or consultant queue. Meanwhile the business change already happened.

The third is cost shape. Per user licensing plus implementation plus validation plus the consultancy required to change anything makes safety systems one of the largest technology lines a mid size company carries, and it scales with headcount rather than with case volume. Companies that build usually do so because the licence and change cost curve stopped matching the size of the problem.

Intake and duplicate detection are where the clock is actually lost

Ask a safety team where their time goes and the answer is rarely the medical assessment. It is getting information into a case in the first place, and deciding whether the thing in front of them is a new case, a follow up to an existing one, or the same event reported by two people.

Duplicate detection is genuinely difficult. A report from a physician and a report from the patient's spouse about the same event will differ in dates, in described symptoms and in patient identifiers. Rule based matching on name, date of birth and event date misses obvious duplicates and flags obvious non duplicates. This is one of the places where a language model earns its keep concretely, not as a chatbot: an unstructured narrative can be turned into candidate structured fields with the source text preserved for verification, and semantically similar narratives can be surfaced for a human duplicate decision. The human still decides. The machine stops the queue from hiding the pair.

The other concrete use is literature screening. Abstracts come in volume, most are irrelevant, and a first pass that ranks them by likelihood of containing a reportable case saves real hours. Both of these are assistive, both keep a human decision point, and both are auditable if you record what was suggested and what the reviewer did. A build that hides an automated decision inside a black box will not survive an inspection, and should not.

Submission is a ledger, not an export

The E2B(R3) message is only the visible part. What determines whether your submission story holds up is the ledger: for every case version, which authorities were notified, on which date, in which format, with which acknowledgement, and where a submission was not required, the recorded reason.

Different regions want different things. The European Union has EudraVigilance with its own rules including non serious reporting timelines, the United States has its expedited pathway and periodic reports, and other markets have their own gateways, local language requirements and in some cases local literature obligations. A case that is expedited in one market may be periodic in another. Partner obligations under safety data exchange agreements add another set of clocks, each negotiated separately in a contract that lives with the legal team.

A custom build should express these as a rules layer over a single case model: obligations are computed from the case, the product, the market and the agreement, and each one becomes a tracked item with a due date and an owner. That is the difference between a system that tells you what is due tomorrow and one that tells you what was late last March.

What a custom build must include

• Multi channel intake: email, call centre, partner E2B, literature, patient support programmes and clinical systems, all landing in one triage queue.
• Assisted extraction from unstructured narratives with the source text preserved and a human confirmation step.
• Duplicate detection that surfaces semantic near matches, with the decision and its rationale recorded.
• Versioned cases with amendment history, and a submission ledger per authority and per partner.
• Seriousness, expectedness against a versioned reference safety information document, and causality assessment as structured fields.
• MedDRA and drug dictionary coding with version control, since dictionary upgrades change coded terms and that has to be traceable.
• Obligation engine computing clocks by product, market, seriousness and agreement, with escalation before the deadline rather than after.
• E2B(R3) generation and gateway submission with acknowledgement handling and negative acknowledgement resolution.
• Aggregate reporting support and reconciliation against partners and against your own clinical databases.
• Full audit trail with 21 CFR Part 11 controls, and validation evidence that stands up in an inspection.

What it costs and how long it takes

Across the regulated workflow platforms Digital Heroes has delivered, a first release covering intake, triage, case processing, coding and E2B(R3) generation runs $180,000 to $400,000 and ships in 20 to 28 weeks. A full safety platform adding partner exchange, literature workflow, aggregate reporting and signal management runs $450,000 to $1,200,000 over 14 to 24 months.

What drives the number up: the number of markets and gateways, because each has its own submission behaviour and acknowledgement handling. Partner safety data exchange agreements, since each is a bespoke set of obligations and formats. MedDRA and dictionary licensing and version management. Computer system validation, which is a genuine workstream and typically adds twenty to thirty percent. Migration of legacy cases, which is heavier than it looks because case versions and submission history have to migrate, not just the latest state.

What keeps it down: one region first, your current product list, and accepting a manual step where volume is genuinely low. Automating a channel that produces eleven cases a year is a bad trade.

Build versus buy, stated plainly

Buy if you have one product in one region and a small case volume. Ennov Safety, a smaller vendor system, or outsourcing case processing to a service provider will cost you far less than a build and get you compliant faster. That is the honest answer for most early companies and we give it regularly.

Build when two or more of these are true. Your annual case volume is in the thousands and growing. You hold authorisations in several regions with genuinely different obligations. You have partner agreements whose reconciliation currently runs on spreadsheets. Your licence and change cost has become one of your largest technology lines and every configuration change takes months. Or intake is your bottleneck rather than assessment, which is the most common pattern we see and the one where a purpose built system creates the clearest gain.

How to choose a developer for pharmacovigilance software

Ask them what happens to a case when follow up information arrives after submission. A credible answer covers versioning, reassessment of seriousness and expectedness, recomputation of obligations, and a new submission with its own ledger entry. An answer about updating the record means they have built a database, not a safety system.

Ask how automated extraction is made auditable. The right answer preserves the source text, records what was suggested, records what the human confirmed or changed, and never lets a machine make a reportability determination on its own. If they cannot explain this in one minute, they have not thought about an inspection.

Ask about validation approach and about how change control works after go live, because a safety system changes constantly as products and markets are added. A validation approach that assumes a frozen system will strangle you within a year.

Ask who owns the code and the validation package and get it in writing before kickoff. You should own the repository, the infrastructure accounts and all validation evidence. At Digital Heroes the client owns all three from the first commit, which matters here because the qualified person responsible for pharmacovigilance is personally accountable for a system they need to be able to change.